Company presentations
NovaGo Therapeutics AG
Novago Therapeutics is a Swiss clinical-stage company specializing in developing treatments for acute spinal cord injury and diabetic retinopathy. As a spin-off from the University of Zürich, we are currently in our Series A funding round, supported by investors such as Pureos Bioventures, Neurimmune, and non-dilutive funding sources.
We are advancing two key assets: Spinal Cord Injury (NG004) and Diabetic Retinopathy (NG050).
Date, time and room information
May 6, 15:15 - 15:30, room Montreal
Category
Clinical stage development company
Title of the presentation
Development of antibody therapeutics to unlock nerve and vessel regeneration in spinal cord injury and diabetic retinopathy in Ophthalmology
Speaker information
| Name | Position | Institution |
|---|---|---|
| Stefan Moese | CEO | NovaGo Therapeutics |
